Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment
The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.
Read more on NPR
Health & Science - August 8, 2019 at 04:00PM - Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment
Không có nhận xét nào:
Đăng nhận xét